Written answers

Tuesday, 19 November 2019

Department of Health

Medicinal Products Reimbursement

Photo of Willie O'DeaWillie O'Dea (Limerick City, Fianna Fail)
Link to this: Individually | In context | Oireachtas source

409. To ask the Minister for Health further to Parliamentary Question No. 279 of 22 October 2019, if osimertinib for adult patients with locally advanced or metastatic EGFRT790M mutation-positive non-small cell lung cancer will be made available from 1 January 2020; if the HSE senior leadership team has discussed the reimbursement of the drug for adult patients with same subsequent to its decision of 9 July 2019 that it was minded to approve the drug; and if he will make a statement on the matter. [47536/19]

Photo of Simon HarrisSimon Harris (Wicklow, Fine Gael)
Link to this: Individually | In context | Oireachtas source

The Health Service Executive has operational responsibility for medicines expenditure, thus the matter has been referred to the HSE for their attention and direct reply to the Deputy.

Comments

No comments

Log in or join to post a public comment.